Contingency Management for Cannabis Use for Persons With HIV
Purpose
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.
Conditions
- Marijuana
- HIV Infections
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name) - Self-report of cannabis use at least once per week in the 6-month period prior to consent - Provide a positive urine toxicology (UTOX) screen for cannabis - Not seeking treatment for cannabis use - Willing to stop using cannabis for 28 days and attend eight study visits over six weeks. - Ability and willingness to provide inform consent - English fluency
Exclusion Criteria
- Currently receiving treatment for cannabis or other drug use disorder - Diagnosed or receiving treatment for a current major depressive or anxiety disorder - Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22) - Positive UTOX screen for opioids - Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Other
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Contingency Management - Cannabis |
Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence. |
|
Recruiting Locations
Houston, Texas 77054
More Details
- Status
- Recruiting
- Sponsor
- The University of Texas Health Science Center at San Antonio